SAR446268

Phase 2Biologic

Sanofi

SAR446268 is one of 3 biologic programs targeting Myotonic Dystrophy Type 1. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myotonic Dystrophy Type 1Recruiting

Myotonic Dystrophy Type 1Phase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Myotonic Dystrophy Type 1

#DrugCompanyPhaseTrials

DYNE-101

DDyne Therapeutics

Phase 3

1 2

PGN-EDODM1

PPepGen Inc

Phase 2

2 3

SAR446268

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1/2Recruiting

Myotonic Dystrophy Type 1

NCT06844214

Clinical

Trials by Indication[1]

Myotonic Dystrophy Type 11 trial

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1

Recruiting· Sanofi logo

Sanofi·Phase 1/2·NCT06844214·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SAR446268. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR446268 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR446268. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Sanofi

SAR446268

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Myotonic Dystrophy Type 11 trial

References

Drug Info

Quick Facts

Related News